Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 1:26 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1969–1992 of 6,600 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multi Center Clear all

Conditions: Anxiety Disorder, Breast Cancer, Depression, Fatigue, Hot Flashes, Pain, Sleep Disorders
Interventions: acupuncture therapy, sham intervention; Procedure
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older · Female only
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Non Therapeutic Body Modification
Interventions: EVOLENCE®; Device
Lead sponsor: Johnson & Johnson Consumer and Personal Products Worldwide; Industry
Eligibility: 18 Years and older
Enrollment: 172 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 11
States / cities: Los Angeles, California • Rancho Mirage, California • Washington D.C., District of Columbia + 8 more

Conditions: Type 1 Diabetes
Interventions: Paradigm 722 sensor augmented pump, Paradigm 715 insulin pump; Device
Lead sponsor: Medtronic MiniMed, Inc.; Industry
Eligibility: 12 Years to 80 Years
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 7
States / cities: Los Angeles, California • Stanford, California • Atlanta, Georgia + 4 more

Conditions: Renal Disease, End Stage Renal Disease
Interventions: Droxidopa; Drug
Lead sponsor: Chelsea Therapeutics; Industry
Eligibility: 18 Years to 79 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Acute Myocardial Infarction, STEMI
Interventions: FDY-5301, Placebo; Drug · Other
Lead sponsor: Faraday Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: Minneapolis, Minnesota • The Bronx, New York

Conditions: Acne Vulgaris
Interventions: CD5789 25 µg/g cream, CD5789 50 µg/g cream, CD5789 100 µg/g cream, Tazarotene 0.1% gel, Vehicle cream; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 12 Years to 35 Years
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 24
States / cities: Birmingham, Alabama • Glendale, California • Marina del Rey, California + 21 more

Conditions: Graft Occlusion, Vascular, Coronary Restenosis, Atherosclerosis
Interventions: BO-653; Drug
Lead sponsor: Chugai Pharma USA; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 29
States / cities: Phoenix, Arizona • Tucson, Arizona • Burlingame, California + 24 more

Conditions: Advanced Cancer, Advanced Solid Tumor
Interventions: ALK202; Drug
Lead sponsor: Shanghai Allink Biotherapeutics Co., Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Margate, Florida • Fairfax, Virginia

Conditions: Obesity, Overweight
Interventions: No treatment given; Other
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 5,360 participants
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Plainsboro, New Jersey

Conditions: Pressure Ulcer
Interventions: AutoloGel; Device
Lead sponsor: Cytomedix; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Pascagaula, Mississippi

Conditions: Type 2 Diabetes
Interventions: ITCA 650 60 mcg/day, sitagliptin; Drug
Lead sponsor: Intarcia Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 535 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 50
States / cities: Birmingham, Alabama • Chandler, Arizona • Long Beach, California + 44 more

Conditions: Myelodysplastic Syndromes
Interventions: MBG453, Placebo, Hypomethylating agents; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 7
States / cities: Duarte, California • New Haven, Connecticut • Boston, Massachusetts + 3 more

Conditions: Hypertension
Interventions: LCZ696, Valsartan, AHU377, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,334 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 38
States / cities: Birmingham, Alabama • Muscle Shoals, Alabama • Chandler, Arizona + 30 more

Conditions: Psoriasis
Interventions: SB414 6%, Vehicle; Drug
Lead sponsor: Novan, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 4
States / cities: Boise, Idaho • Austin, Texas • College Station, Texas + 1 more

Conditions: Rhinoconjunctivitis
Interventions: Cat-PAD, Placebo; Drug
Lead sponsor: Circassia Limited; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 1,408 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 52
States / cities: Rolling Hills Estates, California • Colorado Springs, Colorado • Denver, Colorado + 49 more

Conditions: Type 2 Diabetes
Interventions: ITCA 650, ITCA placebo; Drug · Other
Lead sponsor: Intarcia Therapeutics; Industry
Eligibility: 40 Years and older
Enrollment: 4,156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 34
States / cities: Chandler, Arizona • Hayward, California • Long Beach, California + 28 more

Conditions: KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal, Cancer of Lung, Cancer of the Lung, Lung Cancer, Neoplasms, Lung, Neoplasms, Pulmonary, Pulmonary Cancer, Pulmonary Neoplasms
Interventions: JDQ443, TNO155, tislelizumab; Drug · Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 5
States / cities: Atlanta, Georgia • Boston, Massachusetts • Pittsburgh, Pennsylvania + 1 more

Conditions: Diabetic Foot Ulcers
Interventions: Aurix; Device
Lead sponsor: Nuo Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 760 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 20
States / cities: Arcadia, California • Montebello, California • Visalia, California + 14 more

Conditions: ADHD, Attention Deficit Hyperactivity Disorder, ADHD - Combined Type, Attention Deficit Hyperactivity Disorder Combined, Attention-deficit Hyperactivity, Attention Deficit Hyper Activity
Interventions: CTx-1301-Dexmethylphenidate 12.5 mg (titration only), CTx-1301-Dexmethylphenidate 18.75mg (randomized fixed dose), CTx-1301-Dexmethylphenidate 25mg (randomized fixed dose), CTx-1301-Dexmethylphenidate 37.5 mg (randomized fixed dose), Placebo; Drug
Lead sponsor: Cingulate Therapeutics; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 24
States / cities: Jacksonville, Florida • Maitland, Florida • Orlando, Florida + 21 more

Conditions: Psoriatic Arthritis
Interventions: Zasocitinib, Active Comparator, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 1,088 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 51
States / cities: Chandler, Arizona • Phoenix, Arizona • Fountain Valley, California + 45 more

Conditions: Multiple Sclerosis, Spinal Cord Injury
Interventions: Push Notification Content; Other
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Psoriasis, Inflammation, Coronary Artery Disease, Cardiometabolic Syndrome
Interventions: Orticumab, Placebo; Drug
Lead sponsor: Abcentra; Industry
Eligibility: 30 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 13
States / cities: Scottsdale, Arizona • Santa Monica, California • Tustin, California + 9 more

Conditions: Dementia, Vascular
Interventions: Donepezil Hydrochloride; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 41 Years and older
Enrollment: 974 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 5
States / cities: Hot Springs, Arkansas • St. Petersburg, Florida • Peoria, Illinois + 2 more

Conditions: Crohn's Disease
Interventions: Adalimumab 40 mg eow or ew; Biological
Lead sponsor: Abbott; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 43
States / cities: Berkeley, California • Long Beach, California • San Diego, California + 36 more

Search by objective public record fields.

Acupuncture in Reducing Muscle and Bone Symptoms in Women Receiving Letrozole, Exemestane, or Anastrozole for Stage 0, Stage I, Stage II, or Stage III Breast Cancer

Post Market Safety Study and Effectiveness With Evolence in Subjects With Skin Color Types IV-VI

Use of the Paradigm 722 System to Improve Glycemic Control in Adult and Adolescent Subjects With Type 1 Diabetes

A Multi-Center, Open-Label Study

A Study of Acute Myocardial Infarction Using FDY-5301

Dose Range Study of CD5789 in Acne Vulgaris

A Blinded Study Conducted at Multiple Centers Evaluating Various Doses of an Investigational Agent (BO-653) Against Placebo, for Safety and Effectiveness in Preventing Post-Angioplasty Blood Vessel Re-Closure (Restenosis) in Stented Vessels.

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors

A Study to Characterize the Prevalence of Overweight and Obesity Among Patients With Established Cardiovascular Disease

AutoloGel Therapy to Usual and Customary Care in Pressure Ulcers

A Study to Evaluate ITCA 650 Compared to Sitagliptin as add-on Therapy for the Treatment of Type 2 Diabetes

A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).

Efficacy and Safety of LCZ696A in Patients With Essential Hypertension

A Study Assessing the PK, PD, Safety, and Tolerability of SB414 in Psoriasis

Phase III Cat-PAD Study

A Study to Evaluate Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With ITCA 650

Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

Effectiveness of Aurix Therapy in Diabetic Foot Ulcers

Phase 3 Efficacy and Safety Fixed-Dose Study in Pediatrics (6-17) With ADHD Using CTx-1301

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines

Development of Pain Management JITAI Content in Multiple Sclerosis and Spinal Cord Injury

A Proof-of-Activity Study With Orticumab in Subjects With Psoriasis and Cardiometabolic Risk Factors

Donepezil Hydrochloride (E2020) in Dementia Associated With Cerebrovascular Disease

Remission in Subjects With Crohn's Disease, Open Label Extension